DOSSIER · 13F-HR · Q2 2026

a16z Capital Management, L.L.C.

$14.2B in tracked AUM across 19 positions as of Q2 2026.

AC
CIK 0001540358 · last filed Jun 30, 2026
Total AUM
$14.2B
as of Q2 2026
Holdings
19
positions
Whale Score
87
87
top tier
Activity
no data
changes this Q
AI Analysis · Q2 2026

a16z Capital Management's $1.29B reported 13F captures the publicly-traded equity sleeve of one of Silicon Valley's most recognizable venture-growth firms. The holdings reflect a late-stage private-company and technology-growth portfolio with meaningful weights in public-market proxies for private holdings — consistent with a manager whose primary alpha source is private-venture selection but who uses public-market vehicles as liquidity, duration-matching, or public-equivalent exposure. The WhaleScore of 79 reflects the firm's overall investment performance, which is driven primarily by private-venture returns. The 13F is best read as a liquidity-and-duration overlay rather than the core performance engine.

The holder composition reflects the late-stage positioning: the top positions include public-market proxies for private-venture names (public AI companies, cloud infrastructure, fintech, and biotech names that a16z also holds privately). The overlap between the public and private portfolio is not coincidental — it reflects a16z's practice of building public positions in companies whose private investments have reached the public-company stage or where the firm wants liquid exposure to the thesis while private positions mature.

The WhaleScore of 79 reflects a16z's overall investment performance, which is dominated by private-venture returns. The 13F alone cannot speak to those returns; it can only describe the public-equity overlay. For readers trying to understand a16z's investment process from this filing alone, the most important structural insight is that the public positions are not the main event — they are a liquidity and duration accommodation layered on top of a private-venture engine.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
SPCX
SPACE EXPLORATION TECHN CORP
$12.8B74.9M90.0%
02
NAVN
NAVAN INC
$645M28.2M4.5%
03
RVMD
REVOLUTION MEDICINES INC
$173M921K1.2%
04
META
META PLATFORMS INC
$120M213K0.8%
05
FIG
FIGMA INC
$108M6.0M0.8%
06
BIOA
BIOAGE LABS INC
$79M3.2M0.6%
07
XYZ
BLOCK INC
$77M1.0M0.5%
08
ERAS
ERASCA INC
$52M2.9M0.4%
09
MAZE
MAZE THERAPEUTICS INC
$51M1.7M0.4%
10
GLTO
DAMORA THERAPEUTICS INC
$32M1.2M0.2%

Filing history

2026Q2Jun 30
$14.2B 1001.4%
19 positionsView →
2026Q1Mar 31
$1.3B 18.3%
16 positionsView →
2025Q4Dec 31
$1.6B 263.5%
13 positionsView →
2025Q3Sep 30
$435M 38.9%
8 positionsView →
2025Q2Jun 30
$313M 46.3%
10 positionsLocked
2025Q1Mar 31
$583M 21.8%
9 positionsLocked
2024Q4Dec 31
$745M 34.5%
12 positionsLocked
2024Q3Sep 30
$1.1B 2.9%
13 positionsLocked
2024Q2Jun 30
$1.2B 15.2%
13 positionsLocked
2024Q1Mar 31
$1.4B 14.9%
13 positionsLocked
2023Q4Dec 31
$1.6B
16 positionsLocked